RECOMBINANT PSEUDO-ADENOVIRAL PARTICLE STRAIN EXPRESSING THE CHLAMYDIA TRACHOMATIS CHIMERIC GENE MBL-CT666, A METHOD FOR PREPARING IT, AN IMMUNOGENIC COMPOSITION FOR PROTECTION AGAINST HUMAN UROGENITAL CHLAMYDIOSIS Russian patent published in 2020 - IPC C12N7/00 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology and concerns a strain of recombinant pseudo adenoviral particle expressing a chimeric gene MBL-CT666 Chlamydia trachomatis after its introduction into an individual's body. A recombinant pseudo adenoviral particle strain expressing the chimeric gene MBL-CT666 Chlamydia trachomatis is obtained, which contains the nucleotide sequence SEQ ID NO: 1 chimeric gene MBL-CT666 Chlamydia trachomatis, which after introduction into an individual's body produces a chimeric protein MBL-CT666 Chlamydia trachomatis in the form of the amino acid sequence SEQ ID NO: 2, inducing protection against human urogenital chlamydiosis. Method of obtaining a strain of recombinant pseudo adenoviral particle expressing chimeric gene MBL-CT666 Chlamydia trachomatis consists in that strain is obtained by homologous recombination in E. coli strain BJ5183 between plasmid pShuttle-CMV (#240007, pShuttle-CMV vector, Agilent, US), carrying cassette with chimeric gene MBL-CT666 Chlamydia trachomatis, cloned from plasmid pAL2-T, and adenovirus DNA of human serotype 5 with deletion in region E1 and E3 of adenovirus genome, wherein assembly of recombinant pseudo adenoviral nanoparticles is carried out in cells of line HEK293, Human embryonic kidney 293, after transfection of recombinant DNA pAd-MBL-CT666, wherein as a result of construction, the expression cassette comprises a human cytomegalovirus CMV promoter, target gene – chimeric gene MBL-CT666 Chlamydia trachomatis, pA signal of polyadenylation and is in the region of E1 deletion of adenovirus genome, wherein polymerase chain reaction with specific primers is used, obtaining an immunogenic composition containing a recombinant pseudo adenoviral particle strain expressing the chimeric gene MBL-CT666 Chlamydia trachomatis, for use in an amount of not less than 2×10⁸ PFU/ml, wherein it contains a pharmaceutically acceptable buffer solution of up to 0.5–1.0 ml, a dose volume of 0.5–1.0 ml in a flask.

EFFECT: invention enables to apply an immunogenic composition containing a strain of a recombinant pseudo adenoviral particle expressing a chimeric gene MBL-CT666 Chlamydia trachomatis, as a prime component of a chlamydial vaccine for protection against human urogenital chlamydiosis.

4 cl, 11 dwg, 2 tbl, 7 ex